Schwab Network on $MRNA

Channel profile →Sources cited by the channel: BFA and JP Morgan, Baird, Bank of America, Barclays, Berenberg, Bernstein, Bernstein, with a Jefferies target cut noted, Bilal Little, Bird (analyst firm), CEO, CEO Joe Dominguez, Caner, Citi, Citigroup, Citizens, Daiwa, Dan Deming and Michael Monahan, Dan Ies; Morgan Stanley, Dan Ives, Dan Ives and unnamed analysts, Deutsche Bank, Erit Research, Evercore ISI, Evercore ISI; Dan Ives, Goldman Sachs, JP Morgan Chase, JPMorgan, JPMorgan Chase, James Demerard of Wall Street Research, Jefferies, Jefferies, UBS and Citigroup, Jensen Huang; Dan Ives, KeyBank, Loop Capital, Mattie Natsson, Michael Saylor, Milius (analyst), Morgan Stanley, Northrop, Oppenheimer, Oppenheimer, Freedom Broker, Oracle, PFA analysts, Quantum CEO, RBC, Reddit CEO, Rothschild Redburn, SK Hynix, Seth, Tim Bigham, Tim and KG, Truist, UBS, Wall Street Journal, Wedbush, Wells Fargo, analysts, the street4 entries

Schwab Network has discussed $MRNA in 4 videos since 2026-09-30.

2026-11-05
“The Big 3: HCA, ISRG, MRNA”
AI summary · The speaker likes MRNA, citing Phase 3 data showing a Keytruda-partnered drug cuts skin-cancer-related deaths by about 42% and an upward trend since the start of this year, though not a long-term upward trend. But it failed near old highs around 255 and RSI is unresolved between rising and falling trendlines; a breakout beyond either is needed to clarify bullish vs bearish direction, and a break below the 238.25 5-day EMA could open 219.

Your last name here is also in the healthcare sector, but it's a pharmaceutical company that has fallen a little more than some of the others, down 4.3% for Moderna, which has been making headlines a lot so far this year.

Well, the big picture for Moderna: everyone knows them from their COVID vaccine, but they also have some cool things they're working on, like the partnership with Keytruda and the drug they've provided that's reached Phase 3, which currently shows it can reduce skin cancer-related deaths by about 42%.

So, this is good news. So, I like Moderna in a long-term trend, I shouldn't say a long-term upward trend. It has been on an upward trend since the beginning of this year.

2026-10-23
“Friday's First Moves: MRNA Cancer Vaccine Trial Leaks, DECK Earnings, NCLH Downgrade”Cited source: analysts
AI summary · MRNA fell 5.5% on leaked positive late-stage cancer vaccine data (42% relative cut in recurrence/death risk vs Keytruda alone) — not bad results. Per analysts it's 'buy on rumor, sell on news': a 600% one-year run had priced in a breakthrough, so the drop looks like profit-taking ahead of official phase 3 results.

Diane King Hall is joining me to take a look at Moderna . We talked a little about this yesterday. It was an intense and dramatic sell-off yesterday.

Yesterday, this resulted in a $24 billion reduction in market value. There is ongoing pressure on Moderna today. But that doesn't mean the results were bad. These pressures come after some information regarding cancer vaccine trials was leaked .

We were expecting it to be released at the end of this week. It is still scheduled to be released at the end of this week.

2026-10-23
WDC & BE Slide After Earnings as Crude Crosses $100; MRNA Cancer Vaccine Data Leak
Subscribe or start a trial to unlock this step
2026-09-30Bearish
Wednesday's First Moves: MRNA Downgrade, BA Jet Contract, JBL Earnings
Subscribe or start a trial to unlock this step
2 earlier entries need a subscription
The latest 2 are free to read. Earlier entries keep their date and direction; the text unlocks with a subscription.
Subscribe to read all 2 earlier takes